logo

BFRI

Biofrontera·NASDAQ
--
--(--)
--
--(--)
5.41 / 10
Netural

Biofrontera's fundamentals are average, rated neutral. Key positives include a healthy interest-coverage ratio (15.48) and Days Sales Outstanding of 45.59, which score well. However, both total operating revenue and operating revenue are declining year-over-year (-0.63%), dragging the overall score down. Other factors like Profit-MV and Asset-MV show mixed performance, with the latter negatively impacting the rating. The balance of these elements results in a neutral fundamental outlook.

Fundamental(5.41)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value1.05
Score2/3
Weight13.94%
1M Return7.73%
Total operating revenue (YoY growth rate %)
Value-0.63
Score1/3
Weight-1.04%
1M Return-0.79%
Days sales outstanding
Value45.59
Score2/3
Weight1.55%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight14.20%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight14.22%
1M Return8.45%
PB-ROE
Value-0.44
Score3/3
Weight19.26%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.42%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-0.63
Score1/3
Weight-1.00%
1M Return-0.76%
Asset-MV
Value-0.50
Score3/3
Weight26.33%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight13.96%
1M Return8.41%
Is BFRI undervalued or overvalued?
  • BFRI scores 5.41/10 on fundamentals and holds a Fair valuation at present. Backed by its -1746.87% ROE, -47.28% net margin, -0.58 P/E ratio, -3.71 P/B ratio, and -229.31% earnings growth, these metrics solidify its Netural investment rating.